We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-10.25%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.19B
AUM Growth
-$1.8B
Cap. Flow
-$1.09B
Cap. Flow %
-34.19%
Top 10 Hldgs %
52.73%
Holding
142
New
9
Increased
15
Reduced
47
Closed
31

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$32.3M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$32.3M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.9M
4
LLY icon
Eli Lilly
LLY
+$30M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$24.5M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$143M
2
APLS
Apellis Pharmaceuticals
APLS
+$52.9M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$39.4M
4
NVRO
NEVRO CORP.
NVRO
+$34.5M
5
TVTX icon
Travere Therapeutics
TVTX
+$32.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.5%
2 Financials 0.29%
3 Consumer Discretionary 0.04%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMIC
51
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$13.5M 0.42%
117,876
-3,964
-3% -$465K
TMCI icon
52
Treace Medical Concepts
TMCI
$261M
$13.5M 0.42%
941,192
-30,000
-3% -$505K
VRNA
53
DELISTED
Verona Pharma
VRNA
$12.2M 0.38%
2,915,146
-129,157
-4% -$552K
VRDN icon
54
Viridian Therapeutics
VRDN
$2.18B
$11.2M 0.35%
971,832
-451,221
-32% -$6.06M
CCXI
55
DELISTED
ChemoCentryx, Inc.
CCXI
$10.9M 0.34%
441,680
-1,213,399
-73% -$26.7M
CMAX
56
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$10.9M 0.34%
100,000
-6,222
-6% -$1.07M
LABP
57
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$10.8M 0.34%
1,486,992
– –
DAWN
58
DELISTED
Day One Biopharmaceuticals
DAWN
$9.95M 0.31%
556,047
– –
VRCA icon
59
Verrica Pharmaceuticals
VRCA
$88.8M
$9.68M 0.3%
503,898
+142,857
+40% +$7.18M
CYPH
60
Cypherpunk Technologies Inc
CYPH
$63.3M
$9.14M 0.29%
795,145
– –
CNCE
61
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$9.05M 0.28%
2,150,641
– –
ISO
62
DELISTED
IsoPlexis Corporation Common Stock
ISO
$8.85M 0.28%
4,095,498
– –
KRON
63
DELISTED
Kronos Bio
KRON
$8.81M 0.28%
2,421,142
– –
HLVX
64
DELISTED
HilleVax
HLVX
$8.36M 0.26%
+764,907
New +$9.08M
SLDB icon
65
Solid Biosciences
SLDB
$799M
$8.26M 0.26%
894,170
– –
PRVA icon
66
Privia Health
PRVA
$3.04B
$7.96M 0.25%
273,423
+60,000
+28% +$1.53M
RVNC
67
DELISTED
Revance Therapeutics, Inc.
RVNC
$7.91M 0.25%
572,514
+435,000
+316% +$6.7M
MORF
68
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$7.88M 0.25%
363,197
-404,130
-53% -$11.3M
XBI icon
69
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$7.43M 0.23%
+100,000
New +$7.51M
PNT
70
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$7.31M 0.23%
1,073,995
-120,000
-10% -$918K
SLGC
71
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$6.78M 0.21%
1,500,000
– –
HCAT icon
72
Health Catalyst
HCAT
$161M
$6.74M 0.21%
465,162
-28,500
-6% -$486K
WGS icon
73
GeneDx Holdings
WGS
$1.91B
$6.3M 0.2%
151,515
+75,757
+100% +$5.14M
ICVX
74
DELISTED
Icosavax, Inc. Common Stock
ICVX
$5.98M 0.19%
1,042,850
-336,287
-24% -$2.62M
CCCC icon
75
C4 Therapeutics
CCCC
$389M
$5.78M 0.18%
766,231
-1,316,492
-63% -$11.6M
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Perceptive Advisors held 142 positions worth $3.19B, down 36% from $4.99B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors withdrew a net $1.09B in Q2 2022, closing 31 positions and reducing 47 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $143M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 82% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Perceptive Advisors opened a new position in Seagen Inc. Common Stock worth $39.6M.

  • Perceptive Advisors's largest Q2 2022 buy was Seagen Inc. Common Stock: 224,000 shares worth $39.6M.
  • Perceptive Advisors added most to LYRA THERAPEUTICS INC in Q2 2022, an estimated $32.3M increase.
  • Perceptive Advisors's biggest Q2 2022 reduction was Apellis Pharmaceuticals, cutting an estimated $52.9M.
  • Perceptive Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, selling an estimated $143M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $3.19B portfolio in Q2 2022.
  • Perceptive Advisors opened 9 new positions and closed 31 in Q2 2022.
  • Perceptive Advisors's portfolio value fell 36% quarter-over-quarter to $3.19B.

Based on Perceptive Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.